Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
78.60 ^USD	-9.83%		-16.23%	-23.05%

03-30	Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan	RE
03-30	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI

Transcript : Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026

Published on 02/19/2026 at 10:39 pm GMT - Modified on 02/20/2026 at 01:06 am GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for attending the Guardant Health Q4 2025 Earnings Call. My name is Cameron, and I'll be your moderator for today.

[

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Guardant Health, Inc.

03-30	Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan	RE
03-30	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI
03-24	Guardant Health, Verana Health Collaborate to Advance Precision Medicine	MT
03-24	Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data	CI
03-16	Guardant Health and Manulife Launch Shield Multi-Cancer Detection Test in Hong Kong, Singapore and the Philippines	CI
03-16	Guardant Health to Launch Multicancer Detection Test in Asia With Manulife Financial	MT
03-16	Guardant Health launches Shield multi-cancer detection (Mcd) test in multiple markets in Asia with Manulife partnership	RE
03-11	Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
03-11	Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year	RE
03-10	Guardant Health Inc Announces Shield Blood-Based Screening Test for Colorectal Cancer Is Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	CI
03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
02-19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
02-19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
02-19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT